SCHEDULE 13G: Armistice Capital Discloses Nearly 10% Passive Stake in ZyVersa Therapeutics

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, revealing a 9.99% passive ownership stake in ZyVersa Therapeutics, Inc.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed a Schedule 13G with the SEC.
• The filing indicates that the Reporting Persons beneficially own 285,037 shares of ZyVersa Therapeutics, Inc.'s Common Stock, representing 9.99% of the class.
• Armistice Capital, LLC, a Delaware entity, is the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The shares are held with shared voting power and shared dispositive power by both Armistice Capital, LLC and Steven Boyd.
• The acquisition of these securities was made in the ordinary course of business and not for the purpose of changing or influencing the control of ZyVersa Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the disclosure of a significant passive stake by a reputable institutional investor can be seen as a vote of confidence in the company, potentially attracting further investor interest.

Positives

• The disclosure of a significant 9.99% stake by an institutional investor like Armistice Capital, LLC, and its managing member Steven Boyd, can be interpreted as a vote of confidence in ZyVersa Therapeutics, Inc.'s long-term prospects.
• The passive nature of the investment, as stated in the filing, suggests that the investors are not seeking to influence or change the control of the issuer, which can provide stability.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." Steven Boyd, Managing Member of Armistice Capital, LLC

Industry Context

This filing is a standard disclosure of a significant ownership stake by an institutional investor in a publicly traded company. It does not provide specific insights into broader industry trends but rather reflects an investment decision within the biotechnology or pharmaceutical sector, where ZyVersa Therapeutics operates.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially increasing investor confidence and attracting more interest in the stock.
• Management: The passive nature of the investment indicates that the reporting persons are not seeking to influence management or control, allowing current management to continue their strategic direction without immediate external pressure.

Key Dates

Keywords

ZyVersa Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, SEC filing, Common Stock, Beneficial Ownership, Institutional Investor, Passive Investment, Equity Stake